Figure 4.

Treatment with anti-IL-17 affects the expansion of Ly6G⁺ cells in the spleens of STAT1^−/− mice. Mice were treated as in Fig. 3. At the end of the experiment different populations of splenocytes were analyzed by flow cytometry. (a) Representative dot plot of Ly6G⁺CD11b⁺ cells from STAT1^−/− and anti-IL-17 treated STAT1^−/− primary tumor bearing mice. (b) Frequencies of Ly6G⁺CD11b⁺ cells in the spleens of primary tumor bearing WT, STAT1^−/− or STAT1^−/− treated with anti-IL-17 neutralizing antibody. Frequencies of total (c) CD4⁺ cells and (d) CD8⁺ T cells. Frequencies of activated (e) CD4⁺ and (f) CD8⁺ in the different experimental conditions (WT CNTRL: naive WT mice, STAT1−/− CNTRL: naïve STAT1−/− mice, WT: tumor bearing WT mice, STAT1−/−: tumor bearing STAT1−/− mice, STAT1−/−αIL-17: tumor bearing STAT1−/− mice treated with anti-IL-17. *p = 0.05, **p = 0.01.